Immuron Ltd at HC Wainwright Investment Conference - New York Transcript
Hello, everyone. Thank you for joining us at the H.C. Wainwright 25th Annual Global Investment Conference. For our next presentation, we have Mr. Steven Lydeamore, the CEO of Immuron Limited, a commercial stage company developing a novel class of targeted polyclonal antibodies for difficult-to-treat infections.
Steven, very happy to have you with us. Please go ahead.
Thank you for having me today. Yes, so as mentioned, Immuron is a global biopharmaceutical company developing and commercializing oral immunotherapeutics for gut-mediated diseases. We do have two products on the market, Travelan and Protectyn, both generating revenue.
And in addition to that, we have four clinical programs. We have Travelan and in conjunction with the Navy Medical Research Command (sic- Naval Medical Research Command), we are conducting currently a Phase 2 controlled human infection model trial. We also have the Uniformed Services University conducting a Phase 4 field
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
